Global Aptamers Market, by Type (Nucleic Acid, (DNA-based Aptamers, RNA-based Aptamers, XNA-based Aptamers), Peptide Aptamers), by Application (Diagnostics, Therapeutics, Research and Development), by End User (Biotechnology and Pharmaceutical Companies, Academic and Research Institutions, Contract Research Organization), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5,291.8 Million in 2022 and is expected to exhibit a CAGR of 18.4% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing inorganic growth strategies such as advancement of technologies by key market players is expected to drive the global aptamers market over the forecast period. For instance, in November 2021, Achiko AG, a HealthTech company, announced that they had developed a DNA aptamer-based dengue fever diagnostic test. Aptamers have high affinity and specificity for their target which makes them very effective tool. Achiko AG has seized this unique opportunity to be a market leader in aptamer diagnostics.
Global Aptamers Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been significantly impacted by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on the global aptamers market. For instance, in May 2021, NEC Corporation., an information technology and electronics corporation, and NEC Solution Innovators, a subsidiary of NEC Corporation, announced the development of artificial DNA aptamers that bind to the novel COVID-19 virus. The development stems from the NEC group’s efforts to promote spatial monitoring business using aptamers that includes development of new biosensing systems, such as measuring equipment that can monitor spaces where various viruses, including SARS-CoV-2 and influenza viruses, are present. The aptamers developed by NEC Solution Innovators targets Receptor-Binding Domain which is the key to infection, then it traps the virus by recognizing the three-dimensional structure of the Receptor-Binding Domain and binding very strongly to it.
Global Aptamers Market: Key Developments
For instance, in May 2019, Agilent Technologies, Inc., a life science company, announced that they had signed agreement with SomaLogic Operating Co., Inc., a protein biomarker discovery and clinical diagnostics company. Under this agreement, Agilent Technologies, Inc., will supply customized high-fidelity oligo microarrays to SomaLogic’s novel SOMAscan aptamer assay that are used in the nucleic acid detection. SOMAscan is an aptamer-based proteomics assay that measures human protein analytes in serum, plasma, and other biological with high specificity and sensitivity.
Browse 35 Market Data Tables and 34 Figures spread through 170 Pages and in-depth TOC on “Global Aptamers Market”- Forecast to 2030, Global Aptamers Market, by Type (Nucleic Acid, (DNA-based Aptamers, RNA-based Aptamers, XNA-based Aptamers), Peptide Aptamers), by Application (Diagnostics, Therapeutics, Research and Development), by End User (Biotechnology and Pharmaceutical Companies, Academic and Research Institutions, Contract Research Organization), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/aptamers-market-774
Key Takeaways of the Global Aptamers Market:
- The global aptamers market is expected to exhibit a CAGR of 18.4% during the forecast period due to the increasing inorganic strategies such as product launch by the key players in the market over the forecast period. For instance, in October 2021, Amsbio, a life science research reagent and services company, announced that they had launched new aptamers for targeting COVID-19 proteins to aid development of new kits and assays.
- Among type, Nucleic acid aptamers are estimated to hold a dominant position in the global aptamers market over the forecast period owing to the growing interest in aptamer profession by research and development. For instance, in January 2020, according to the data published in Journal of Biomedical Science, nucleic acid aptamers are used in the treatment of microbial infection, regarding their promising anti-biofilm and antimicrobial activities, they can inhibit or reduce the effects of bacterial toxins and inhibit pathogen invasion to immune cell.
- Among regions, North America is estimated to account for the largest market share in the global aptamers market over the forecast period. For instance, in July 2022, IVERIC bio, Inc., a biopharmaceutical company, announced that they will develop and commercialize new formulations of Zimura by using silica based sustained release technology, for the treatment of age-related macular degeneration. Zimura is a chemically synthesized RNA aptamer and amendable to injectable sustained released formulations.
- Major players operating in the global aptamers market include Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc.
